Anecortave acetate

Abstract

This manuscript reviews the pharmacotherapeutics of the novel, angiostatic cortisene, anecortave acetate suspension, for the treatment of age-related macular degeneration. The chemistry, pharmacokinetics and pharmacodynamics of anecortave acetate are discussed, and the results of the multi-centre, randomised, controlled clinical trials for the treatment of subfoveal choroidal neovascularisation in age-related macular degeneration summarised. It also discusses ongoing clinical trials involving anecortave acetate for dry and wet age-related macular degeneration.

Keywords::

• anecortave acetate
• angiogenesis
• angiostatic
• choroidal neovascularisation
• cortisene
• juxtascleral
• macular degeneration
• periocular

View correction statement:

Erratum